CN116763813A - Medical hyaluronic acid skin repair gel - Google Patents
Medical hyaluronic acid skin repair gel Download PDFInfo
- Publication number
- CN116763813A CN116763813A CN202310562612.9A CN202310562612A CN116763813A CN 116763813 A CN116763813 A CN 116763813A CN 202310562612 A CN202310562612 A CN 202310562612A CN 116763813 A CN116763813 A CN 116763813A
- Authority
- CN
- China
- Prior art keywords
- parts
- prepared
- weight
- following components
- carbomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 25
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 25
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 25
- 230000008439 repair process Effects 0.000 title claims abstract description 24
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 38
- 229960001631 carbomer Drugs 0.000 claims abstract description 38
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 16
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 16
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 15
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims abstract description 13
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 13
- 229960004418 trolamine Drugs 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000004973 liquid crystal related substance Substances 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 230000009972 noncorrosive effect Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- -1 polyethylene Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 abstract description 29
- 208000003251 Pruritus Diseases 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 5
- 206010015150 Erythema Diseases 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 5
- 206010037660 Pyrexia Diseases 0.000 abstract description 5
- 206010040844 Skin exfoliation Diseases 0.000 abstract description 5
- 206010000496 acne Diseases 0.000 abstract description 5
- 230000035618 desquamation Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 231100000321 erythema Toxicity 0.000 abstract description 5
- 230000000474 nursing effect Effects 0.000 abstract description 5
- 239000011241 protective layer Substances 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 208000010668 atopic eczema Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 206010012435 Dermatitis and eczema Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229960002744 mometasone furoate Drugs 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010014190 Eczema asteatotic Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010058898 Hand dermatitis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010036087 Polymorphic light eruption Diseases 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application belongs to the technical field of biological medicine, and in particular relates to medical hyaluronic acid skin repair gel which comprises sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific matching proportion of a formula: wherein, the sodium hyaluronate is prepared from the following components in parts by weight: 3-5 parts; the carbomer is prepared from the following components in parts by weight: 1-3 parts; the triethanolamine is prepared from the following components in parts by weight: 3-5 parts; the glycerol is prepared from the following components in parts by weight: 3-5 parts; the glycerol caprylate is prepared from the following components in parts by weight: 1-2 parts; the skin care product has reasonable structure, and forms a protective layer on the surface of skin in the use process, so as to relieve erythema, pruritus, stinging, fever, dryness and desquamation symptoms caused by skin inflammation; and (3) nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations.
Description
Technical Field
The application relates to the technical field of biological medicines, in particular to medical hyaluronic acid skin repair gel.
Background
Dermatitis is a more common clinical disease, and is classified into contact dermatitis, eczema, allergic dermatitis and other types of dermatitis according to the dermatitis classification recommended by the world allergic organization. Among them, eczema which can be further classified among contact dermatitis (cosmetics, diapers, dermatitis lacquer) caused by contact with foreign substances, such as atopic dermatitis, seborrheic dermatitis, stasis dermatitis, self-sensitive dermatitis, periwound infectious dermatitis, eczema, chronic lichen simplex, tinea mycosis, hand dermatitis, polymorphous light eruption, etc.; eczema which cannot be further classified is perianal eczema, calf eczema, scrotum eczema, breast eczema, external ear eczema, spring eczema, summer eczema, prurigo and the like.
Dermatitis and eczema are often used synonymously to refer to an inflammation of the skin, representing the allergic reaction of the skin to chemicals, proteins, bacteria and fungi.
At present, most of the dermatitis therapeutic drugs mainly used by Western medicine are corticosteroids, and antihistamines and antibiotics are taken orally, wherein the antihistamines mainly play a role in relieving static itching, the antibiotics are used for treating infected skin lesions, and the external application of the corticosteroids-containing drugs is remarkable in treating the mild dermatitis. However, in recent years, skin damage caused by external hormone preparations has increased dramatically, and adverse reactions have become remarkable, which has become a social problem of great concern. If the corticosteroid-containing drugs are used frequently or in large amounts for a long period of time, they are susceptible to skin that is sensitive and may be accompanied by systemic skin sensitivity; the hormone can be absorbed into blood circulation through skin for a long time and a large amount of external use, thereby causing diabetes and the like; abuse of antibiotics may result in enhanced bacterial resistance and reduced immune function, resulting in repeated and difficult recovery.
For this reason, chinese patent document CN103006686a discloses a functional preparation for adjuvant therapy of atopic dermatitis and a preparation method thereof, which comprises the following raw materials by weight: 0.2 to 1 part of sodium hyaluronate, 5 to 10 parts of emulsifying thickener and 5 to 10 parts of grease, and deionized water is added to 100 parts. The patent document is a functional preparation containing sodium hyaluronate, and the combination of mometasone furoate emulsifiable paste can obviously improve the symptoms of dry eczema, can effectively restore the skin barrier function, reduce recurrence, and has better curative effect than single mometasone furoate emulsifiable paste; can be used for adjuvant treatment of dermatitis and eczema, with good therapeutic effect and safety, and reduced recurrence. However, this technique has an adjuvant therapeutic effect only on atopic dermatitis, and is not universal.
Based on the above, we propose a medical hyaluronic acid skin repair gel.
Disclosure of Invention
This section is intended to outline some aspects of embodiments of the application and to briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section as well as in the description of the application and in the title of the application, which may not be used to limit the scope of the application.
The present application has been made in view of the problems occurring in the prior art.
Therefore, the application aims to provide medical hyaluronic acid skin repair gel, which can form a protective layer on the surface of skin in the using process and is used for relieving erythema, pruritus, stinging, fever and dry desquamation symptoms caused by skin inflammation; and (3) nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations.
In order to solve the technical problems, according to one aspect of the present application, the following technical solutions are provided:
the medical hyaluronic acid skin repair gel comprises sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of a formula:
wherein, the liquid crystal display device comprises a liquid crystal display device,
the sodium hyaluronate is prepared from the following components in parts by weight: 3-5 parts;
the carbomer is prepared from the following components in parts by weight: 1-3 parts;
the triethanolamine is prepared from the following components in parts by weight: 3-5 parts;
the glycerol is prepared from the following components in parts by weight: 3-5 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 1-2 parts;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 4-6 parts;
the hexanediol is prepared from the following components in parts by weight: 1-2 parts;
the purified water is prepared from the following components in parts by weight: 50-100 parts.
As a preferred embodiment of the medical hyaluronic acid skin repair gel of the present application, wherein: the preparation method of the carbomer comprises the steps of adding quantitative water into a stirrer, rapidly stirring, slowly adding carbomer, and continuously stirring for 1-2 hours after the carbomer is added, so that the carbomer is fully swelled.
As a preferred embodiment of the medical hyaluronic acid skin repair gel of the present application, wherein: regulating pH to 6-10 with triethanolamine or sodium hydroxide solution, dispersing resin particles in cold water, sieving carbomer with screen under stirring at 500-800rpm, and obtaining gel matrix carbomer.
As a preferred embodiment of the medical hyaluronic acid skin repair gel of the present application, wherein: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and split charging the gel into polyethylene bottles to obtain the medical hyaluronic acid skin repair gel.
As the medical hyaluronic acid skin repair agent, the application is used for repairing the skinA preferred embodiment of the gel, wherein: the using method is as follows: external use for cleaning affected part skin, opening external package, squeezing gel, and mixing at a ratio of 0.1g/cm 2 The wound surface is uniformly coated for 3 times a day.
As a preferred embodiment of the medical hyaluronic acid skin repair gel of the present application, wherein: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Compared with the prior art, the application has the beneficial effects that:
forming a protective layer on the skin surface for relieving symptoms of erythema, itching, stinging, fever, dryness and desquamation caused by skin inflammation; and (3) nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations.
Detailed Description
The following detailed description of the present application will provide further details in order to make the above-mentioned objects, features and advantages of the present application more comprehensible.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present application, but the present application may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present application is not limited to the specific embodiments disclosed below.
In order to make the objects, technical solutions and advantages of the present application more apparent, embodiments of the present application will be described in further detail below.
The application provides the following technical scheme: a medical hyaluronic acid skin repairing gel is used for forming a protective layer on the surface of skin during the use process, and is used for relieving erythema, pruritus, stinging, fever and dry desquamation symptoms caused by skin inflammation; nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations;
example 1
The medical hyaluronic acid skin repair gel comprises sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of a formula:
wherein, the liquid crystal display device comprises a liquid crystal display device,
the sodium hyaluronate is prepared from the following components in parts by weight: 3 parts;
the carbomer is prepared from the following components in parts by weight: 1 part;
the triethanolamine is prepared from the following components in parts by weight: 3 parts;
the glycerol is prepared from the following components in parts by weight: 3 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 1 part;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 4 parts;
the hexanediol is prepared from the following components in parts by weight: 1 part;
the purified water is prepared from the following components in parts by weight: 50 parts.
Wherein: the preparation method of the carbomer comprises the steps of adding quantitative water into a stirrer, rapidly stirring, slowly adding carbomer, and continuously stirring for 1-2 hours after the carbomer is added, so that the carbomer is fully swelled.
Wherein: regulating pH to 6-10 with triethanolamine or sodium hydroxide solution, dispersing resin particles in cold water, sieving carbomer with screen under stirring at 500-800rpm, and obtaining gel matrix carbomer.
Wherein: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and split charging the gel into polyethylene bottles to obtain the medical hyaluronic acid skin repair gel.
Wherein: the using method is as follows: external use for cleaning affected part skin, opening external package, squeezing gel, and mixing at a ratio of 0.1g/cm 2 The wound surface proportion is uniformIs applied 3 times daily.
Wherein: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Example 2
The medical hyaluronic acid skin repair gel comprises sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of a formula:
wherein, the liquid crystal display device comprises a liquid crystal display device,
the sodium hyaluronate is prepared from the following components in parts by weight: 5 parts;
the carbomer is prepared from the following components in parts by weight: 3 parts;
the triethanolamine is prepared from the following components in parts by weight: 5 parts;
the glycerol is prepared from the following components in parts by weight: 5 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 2 parts;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 6 parts;
the hexanediol is prepared from the following components in parts by weight: 2 parts;
the purified water is prepared from the following components in parts by weight: 100 parts.
Wherein: the preparation method of the carbomer comprises the steps of adding quantitative water into a stirrer, rapidly stirring, slowly adding carbomer, and continuously stirring for 1-2 hours after the carbomer is added, so that the carbomer is fully swelled.
Wherein: regulating pH to 6-10 with triethanolamine or sodium hydroxide solution, dispersing resin particles in cold water, sieving carbomer with screen under stirring at 500-800rpm, and obtaining gel matrix carbomer.
Wherein: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and split charging the gel into polyethylene bottles to obtain the medical hyaluronic acid skin repair gel.
Wherein: the using method is as follows: external use for cleaning affected part skin, opening external package, squeezing gel, and mixing at a ratio of 0.1g/cm 2 The wound surface is uniformly coated for 3 times a day.
Wherein: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Forming a protective layer on the skin surface for relieving symptoms of erythema, itching, stinging, fever, dryness and desquamation caused by skin inflammation; and (3) nursing closed wound surfaces after the acne is healed, skin allergy, laser photons and other minimally invasive operations.
Although the application has been described hereinabove with reference to embodiments, various modifications thereof may be made and equivalents may be substituted for elements thereof without departing from the scope of the application. In particular, the features of the disclosed embodiments may be combined with each other in any manner as long as there is no structural conflict, and the exhaustive description of these combinations is not given in this specification merely for the sake of omitting the descriptions and saving resources. Therefore, it is intended that the application not be limited to the particular embodiment disclosed, but that the application will include all embodiments falling within the scope of the appended claims.
Claims (6)
1. A medical hyaluronic acid skin repair gel, characterized in that: the preparation method comprises the steps of preparing sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water according to the specific proportion of a formula:
wherein, the liquid crystal display device comprises a liquid crystal display device,
the sodium hyaluronate is prepared from the following components in parts by weight: 3-5 parts;
the carbomer is prepared from the following components in parts by weight: 1-3 parts;
the triethanolamine is prepared from the following components in parts by weight: 3-5 parts;
the glycerol is prepared from the following components in parts by weight: 3-5 parts;
the glycerol caprylate is prepared from the following components in parts by weight: 1-2 parts;
octanoyl hydroxamic acid is prepared from the following components in parts by weight: 4-6 parts;
the hexanediol is prepared from the following components in parts by weight: 1-2 parts;
the purified water is prepared from the following components in parts by weight: 50-100 parts.
2. A medical hyaluronic acid skin repair gel according to claim 1, characterized in that: the preparation method of the carbomer comprises the steps of adding quantitative water into a stirrer, rapidly stirring, slowly adding carbomer, and continuously stirring for 1-2 hours after the carbomer is added, so that the carbomer is fully swelled.
3. A medical hyaluronic acid skin repair gel according to claim 2, characterized in that: regulating pH to 6-10 with triethanolamine or sodium hydroxide solution, dispersing resin particles in cold water, sieving carbomer with screen under stirring at 500-800rpm, and obtaining gel matrix carbomer.
4. A medical hyaluronic acid skin repair gel according to claim 1, characterized in that: the specific preparation process is as follows:
sequentially adding sodium hyaluronate, carbomer, triethanolamine, glycerol caprylate, octanoyl hydroxamic acid, hexanediol and purified water, fully dissolving, stirring at room temperature, stirring to obtain slurry, and centrifuging to remove foam; finally, checking and split charging the gel into polyethylene bottles to obtain the medical hyaluronic acid skin repair gel.
5. A medical hyaluronic acid skin repair gel according to claim 1, characterized in that: the using method is as follows: external use for cleaning affected part skin, opening external package, squeezing gel, and mixing at a ratio of 0.1g/cm 2 The wound surface is uniformly coated for 3 times a day.
6. A medical hyaluronic acid skin repair gel according to claim 1, characterized in that: transportation and storage adjustments were as follows: preserving at normal temperature, and storing in dry, ventilated and non-corrosive environment; during transportation, heavy pressure, direct sunlight and rain and snow are prevented.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310562612.9A CN116763813A (en) | 2023-05-18 | 2023-05-18 | Medical hyaluronic acid skin repair gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310562612.9A CN116763813A (en) | 2023-05-18 | 2023-05-18 | Medical hyaluronic acid skin repair gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116763813A true CN116763813A (en) | 2023-09-19 |
Family
ID=88007194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310562612.9A Pending CN116763813A (en) | 2023-05-18 | 2023-05-18 | Medical hyaluronic acid skin repair gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116763813A (en) |
-
2023
- 2023-05-18 CN CN202310562612.9A patent/CN116763813A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK169018B1 (en) | Use of sulphated sugar species | |
| US5583119A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| WO2019223699A1 (en) | Biological polysaccharide for preventing and treating acne and steroid-dependent dermatitis and use thereof | |
| CN101669889B (en) | Sunscreen lipstick with repair function and preparation method thereof | |
| CN108653129B (en) | Skin dressing containing natural plant anti-allergy composition | |
| CN104622897A (en) | Skin moisturizer for treating skin disease and preparation method of skin moisturizer | |
| JPH01503061A (en) | Topical metronidazole preparations | |
| CN1383379A (en) | Method of treatment of seborrheic dermatitis | |
| CN101664379A (en) | Salicylic acid gelling agent and preparation method thereof | |
| EP0676963A1 (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| CN111317690A (en) | Anti-allergy essence containing industrial hemp leaf extract and preparation method thereof | |
| WO2016008283A1 (en) | Preparation method for antithyroid ointment for external application | |
| CN116763813A (en) | Medical hyaluronic acid skin repair gel | |
| US3043745A (en) | Allantoin and coal tar extract composition and treatment of psoriasis | |
| JPH0395106A (en) | Use of sucralfate wet gel as locally active carrier for medicine or toiletry | |
| US4119713A (en) | Analgesic and anti-inflammatory composition | |
| CN116687956A (en) | Medical hyaluronic acid skin repair liquid | |
| CN114344189B (en) | Sialic acid-containing water-in-oil type skin cream and preparation method thereof | |
| CN112007059B (en) | Medical skin repairing gel, preparation method and application thereof in preparation of medicine for treating dermatitis | |
| EP1737467B1 (en) | Composition for the treatment of skin conditions | |
| US6225356B1 (en) | Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea | |
| ZA200309976B (en) | Use of corrinoids in the treatment of skin diseases. | |
| CN113230154B (en) | Composition with anti-allergy, relieving and anti-inflammation effects and preparation method and application thereof | |
| CN104771405A (en) | Compound terbinafine preparation and applications thereof | |
| CN1078396A (en) | Medicine for treating dermatosis and manufacture method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |